TXMD — Stock Film
STOCK FILMSCENE 1/11TXMD · $2.06
Stock Expert AI presents
TXMD
TherapeuticsMD, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
TherapeuticsMD, Inc. A quick introduction.

On the stock market since 2007, it operates in the world of health and science. It has 1 employee. Now — the numbers.

on the stock market since 2007
1 employee
$24M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are moving sideways.

No real growth (4% a year). Red columns mark years that ended in a loss.

$2.6M
2021
$70M
2022
$1.3M
2023
$1.8M
2024
$3M
2025
In the vault right now:
$0
DEBT: $6.1M
At this pace, that money lasts about 13.2 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

Every quarter, analysts set a profit bar.
How many of the last 6 did the company clear?
2 / 6
EXPECTATIONS MET OR BEATEN
2
Aug 2024
Nov 2024
Mar 2025
Mar 2026
May 2026
Aug 2026
2 TIMES IN THE LAST 6 QUARTERS
It misses the bar more often than not.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
55
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
22
very weak

Clearly below the class average.

VALUATION
58
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
76
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
49
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $3.0M a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 17 buys and 6 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Running at a loss

A loss of $569K against $3.0M in annual sales.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 22/100.

3
THE RISKS · 3/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 49/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, TXMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: TXMD is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film